Shanghai Hansoh BioMedical

Shanghai Hansoh BioMedical is the Shanghai-based innovative R&D subsidiary of Hansoh Pharma, a major Chinese pharmaceutical group focused on oncology, anti-infectives, central nervous system, metabolic, and autoimmune diseases. The company was founded in 2011 and operates from Shanghai Zhangjiang, where it conducts medicinal chemistry, biologics research, and broader drug discovery and development activities. As part of Hansoh Pharma, it contributes to a large innovation pipeline that includes small molecules, ADCs, bispecific antibodies, and siRNA programs, with multiple assets in clinical development and several innovative products already commercialized at the group level. Public disclosures and corporate records indicate that Shanghai Hansoh BioMedical is an active, wholly owned subsidiary of Jiangsu Hansoh Pharmaceutical Group and has also been a named licensor in global partnering transactions, including Roche and GSK deals tied to pipeline assets. The entity appears to function primarily as an R&D and technology platform company within the broader Hansoh organization rather than as a standalone listed operating company.